logo
Plus   Neg
Share
Email

FDA Approves Catalyst Pharma's Drug To Treat Rare Autoimmune Disorder

The U.S. Food and Drug Administration approved Firdapse or amifampridine tablets for the treatment of Lambert-Eaton myasthenic syndrome or LEMS in adults. LEMS is a rare autoimmune disorder that affects the connection between nerves and muscles and causes weakness and other symptoms in affected patients. This is the first FDA approval of a treatment for LEMS. The FDA granted the approval of Firdapse to Catalyst Pharmaceuticals Inc. (CPRX).

In people with LEMS, the body's own immune system attacks the neuromuscular junction (the connection between nerves and muscles) and disrupts the ability of nerve cells to send signals to muscle cells. LEMS may be associated with other autoimmune diseases, but more commonly occurs in patients with cancer such as small cell lung cancer, where its onset precedes or coincides with the diagnosis of cancer. The prevalence of LEMS is estimated to be three per million individuals worldwide.

The most common side effects experienced by patients in the clinical trials were burning or prickling sensation (paresthesia), upper respiratory tract infection, abdominal pain, nausea, diarrhea, headache, elevated liver enzymes, back pain, hypertension and muscle spasms. Seizures have been observed in patients without a history of seizures. Patients should inform their health care provider immediately if they have signs of hypersensitivity reactions such as rash, hives, itching, fever, swelling or trouble breathing.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
DISH Network Corp. (DISH) Wednesday reported a profit for the fourth-quarter that increased about 15 percent from last year, but quarterly revenue decreased 2 percent. Both earnings per share and revenue top analysts' estimates. Net Pay-TV subscribers for the quarter decreased by about 194,000 from the prior quarter. Advanced Bionics LLC, the US unit of Swiss hearing aid maker Sonova Holding AG, has recalled certain un-implanted cochlear implant devices due to decreased hearing performance. The recall would incur costs in the range of 40 million Swiss francs to 50 million francs. In a statement, Sonova said that... Shares of Deutsche Telekom AG were gaining around 4 percent in the morning trading after the German telecom giant reported Wednesday a profit in its fourth quarter, compared to last year's loss. The company also projects higher results in fiscal 2020. For the new year, Deutsche Telekom expects another increase in revenue from fiscal 2019 revenue of 80.5 billion euros.
Follow RTT
>